Roivant Sciences Reports Q1 EPS of 33c, Revenue of $2.17M, and Initiates $1.5B Share Buyback Program

Roivant Sciences reported Q1 EPS of 33 cents, beating consensus estimates of 23 cents. Revenue was $2.17M, falling short of the consensus estimate of $6.92M. CEO Matt Gline expressed pride in the company's execution and clinical progress, and announced an additional $1.5 billion share repurchase program. The company is awaiting a DM trial readout and preparing for the potential launch of brepocitinib, which could bring significant benefits to patients with high unmet need.

Roivant Sciences Ltd. (ROIV) reported its financial results for the first quarter ended June 30, 2025, with earnings per share (EPS) of 33 cents, surpassing consensus estimates of 23 cents. The company's revenue totaled $2.17 million, falling short of the consensus estimate of $6.92 million. CEO Matthew Gline expressed pride in the company's execution and clinical progress, highlighting the completion of the initial $1.5 billion share repurchase program and announcing an additional $1.5 billion share repurchase program [1].

The company is awaiting the readout of its dermatomyositis (DM) trial, with topline data expected in the second half of 2025. Gline noted that the company is preparing for the potential launch of brepocitinib, which could provide significant benefits to patients with high unmet need. The company's strong financial position, with $4.5 billion in cash as of June 30, 2025, supports its ongoing clinical trials and potential launches.

Roivant Sciences' clinical pipeline remains robust, with several trials in progress, including registrational studies for IMVT-1402 in Graves' disease and Sjögren's disease, as well as proof-of-concept studies in non-infectious uveitis and cutaneous sarcoidosis. The company's commitment to shareholder returns is evident in its share repurchase programs, which have reduced the share count by over 15% [2].

The company's ongoing litigation with Moderna and Pfizer/BioNTech continues to progress, with a U.S. jury trial scheduled for March 2026 and international hearings expected in the first half of 2026. Despite these challenges, Roivant Sciences maintains a positive outlook, with a strong focus on clinical execution and the potential for transformative therapies.

References:
[1] https://seekingalpha.com/news/4483334-roivant-plans-500m-new-share-repurchase-as-brepocitinib-data-readout-nears
[2] https://investor.roivant.com/news-releases/news-release-details/roivant-reports-financial-results-first-quarter-ended-june-30-1